Bold Moves

Deliver first-in-class science

Transform our go-to-market model

Pfizer partners with Direct Relief to provide critical
​​​​​​​COVID-19 supplies to hospitals

Fighting back against a global pandemic requires cooperation, collaboration and teamwork. As part of Pfizer’s broader COVID-19 response, we are proud to partner with Direct Relief, a humanitarian aid organization dedicated to improving the health and lives of people affected by poverty or emergencies across 80 countries worldwide.

Pfizer has always been committed to deploying resources in times of crisis, including leveraging a long-standing partnership with Direct Relief to help alleviate some of the issues facing hospitals overwhelmed by an influx of patients.

In the weeks leading up to a surge in hospitalizations for COVID-19, Direct Relief pharmacist Alycia Clark foresaw a looming shortage of medication.

“We were asking for products for intensive care units when the first cases were just hitting the U.S., and we had to take a risk,” Clark said. “Now, hospitals are stocked out, pharmacies are stocked out, and manufacturers are stocked out.”

Pfizer has donated tens of thousands of units of antibiotics and vasopressor therapies for Direct Relief’s COVID-19 ICU Rx Modules, aka “push packs.”

She began putting together a program to assemble, stockpile and quickly distribute essential supplies to hospitals in need, eventually securing supplies from a collection of pharmaceutical companies. As a longstanding partner in Direct Relief’s efforts, including the donation of medicine to millions of HIV/AIDS patients in Africa via the Diflucan Partnership program, and helping provide more than 1 million doses of opioid overdose-reversing naloxone to American health centers through the Naloxone Access Program, Pfizer was ready to contribute to the COVID-19 response.

Amid this global health crisis, we understand the need for immediate and significant philanthropic and private sector contributions to help sustain partners who are working on the front lines to save lives.” At Pfizer, we believe it is our responsibility to help protect the most vulnerable from this disease. We are putting the full weight of our resources behind our comprehensive COVID-19 response.”​​​​​​​

Caroline Roan

Vice President of Global Health & Patient Access, Pfizer and President of The Pfizer Foundation

Pfizer has donated tens of thousands of units of antibiotics and vasopressor therapies for Direct Relief’s COVID-19 ICU Rx Modules, aka “push packs.” These modules have been endorsed by the Society of Critical Care Medicine (SCCM) and have enabled treatment for thousands of hospitalized patients with serious COVID-19 infections suffering from bacterial infections, such as pneumonia and septic shock.

"SCCM was very pleased to partner with Direct Relief on the distribution of these valuable medications and equipment for intensive care professionals on the front lines of this pandemic," said David J. Martin, CAE, CEO/Executive Vice President of the Society of Critical Care Medicine. "Direct Relief was there when our hospitals and ICUs were overwhelmed with critically ill COVID-19 patients, and we can't thank the organization enough for their dedication and commitment to supporting the critical care community during these unprecedented times."​​​​​​​

The push packs were shipped out at the beginning of April and have since been delivered to hospitals all over the globe. Pfizer is proud to team with Direct Relief and support the global health care community as just one small part of our comprehensive response to combating the pandemic.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories